13 11 20

Information and support

  • Get informed
  • Get support
  • Cut my risk
  • Get involved
  • Research
  • CA209-7CK

    Acronym: 

    CA209-7CK

    ACTRN/NCT /ethics: 

    NCT04146324

    Scientific title: 

    A prospective, observational study in patients receiving adjuvant nivolumab therapy for resected melanoma in Australia

    Summary of trial and patient characteristics

    Cancer Type Melanoma & other skin
    Trial Type Early detection, diagnosis, prognosis
    Phase All phases Tumour Stream Melanoma
    Age Range 18 years and older Cancer Stage All stages
    Sex Both Anticipated Start Date 2019-10-31
    Molecular Target Anticipated End Date 2025-07-09
    Cancer Type Melanoma & other skin
    Trial Type Early detection, diagnosis, prognosis
    Phase All phases
    Age Range 18 years and older
    Sex Both
    Molecular Target
    Tumour Stream Melanoma
    Cancer Stage All stages
    Anticipated Start Date 2019-10-31
    Anticipated End Date 2025-07-09

    Trial Summary

    A prospective, observational study in patients receiving adjuvant nivolumab therapy for resected melanoma in Australia

    Lay Summary

    A prospective, observational study in patients receiving adjuvant nivolumab therapy for resected melanoma in Australia

    Sponsor / Cooperative group

    Bristol-Myers Squibb

    Participating Hospitals

    Hospital Clinical Trial Coordinator Email Phone Principal Investigator Recruitment Status
    The Queen Elizabeth Hospital Pamela Cooper pamela.cooper@sa.gov.au 08 8222 6140 Dr Rachel Roberts-Thomson Not Yet Recruiting